

EL 477 037 113 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Rozhon *et al.*

Serial No.: 09/712,033

Group Art Unit: 1651

Filed: November 14, 2000

Examiner: I. Marx

For: ENTERIC FORMULATIONS OF
PROANTHOCYANIDIN POLYMER
ANTIDIARRHEAL COMPOSITIONS

New Attorney Docket No.: 11133-004
Former Attorney Docket No.: 7032-073

STATEMENT OF STEVEN R. KING, PH.D.

Attention: Office of Petitions
Assistant Commissioner for Patents
Box DAC
Washington, D.C. 20231

I, Steven R. King, Ph.D., declare and state as follows:

1. I was employed for twelve (12) years at Shaman Pharmaceuticals, Inc. (Shaman), serving as Vice President Ethnobotany and Conservation and as Chief Operating Officer until Shaman filed for bankruptcy protection, through the bankruptcy proceedings and still serve as Chief Operating Officer for the bankrupt company which has been divested of all its assets.
2. In early 2001, Shaman Pharmaceuticals, Inc. (Shaman), then assignee of record, was experiencing financial difficulties and on January 5, 2001, filed for Chapter 11 Bankruptcy protection with the Northern District of California. By that point in time, Shaman's in-house patent counsel had left and I as Chief Operating Officer and as the Responsible Person for Bankruptcy was responsible for all intellectual property matters at Shaman. On May 3, 2001, after fully discussing the matter with me, Pennie & Edmonds LLP (Pennie) Shaman's outside patent counsel, filed a Petition for permissive withdrawal as attorneys for failure to pay for services in connection with the above-application. On that same day, Pennie forwarded to me the entire original file for the above-identified application with a letter explaining that there was an outstanding Notice of Missing Parts (Notice) and that the filing fee was due on June 18, 2001, payable with extension fees until October 18, 2001. I received the file with the explanatory letter together with a list of outstanding deadlines for maintenance fees, responses to Official Actions, requests for examination, etc. that needed to be addressed from that time until the end of 2001. I took note of the information, but,

RECEIVED

NY2 - 1330870.1

JUL 11 2002

OFFICE OF PETITIONS

unfortunately through an inadvertent error did not appreciate that a response needed to be filed to the Notice on or by October 18, 2001 in order to keep the application in good standing.


3. From that time until the end of 2001, as the Responsible Person in Bankruptcy, I was engaged in managing and overseeing all aspects of the disposition of Shaman's assets, including but not limited to maintenance and prosecution of the intellectual property of Shaman as the company was in the process of selling its assets under the supervision of the bankruptcy court. From September 15, 2001 to December 17, 2001, I worked as an unpaid employee of Shaman to assist in the sale or disposition of Shaman's assets. In connection with the sale, during September - October 2001, I assisted with the preparation of information, to be submitted with a Motion, relating to Shaman's intellectual property assets including the above-identified application. It was my understanding that the above-identified application was in good standing and I did not appreciate that a Response was due on October 18, 2001. A Motion to sell Shaman's intellectual property assets including the application was filed on October 19, 2001 with the bankruptcy court.
4. On December 12, 2001, the United States Bankruptcy Court for the Northern District of California granted an Order approving sale and assignment of the assets including the application of Shaman Pharmaceuticals, Inc. to PS Pharmaceuticals, Inc.
5. I am presently under contract with the new company, PS Pharmaceuticals, Inc. (PS Pharm.). My position at PS Pharm. is Vice President of Ethnobotany and Conservation.
6. On April 16, 2002, PS Pharm. retained Pennie & Edmonds LLP (Pennie) as outside patent counsel.
7. It was only on or about June 5, 2002 after I requested Pennie to review the status of the intellectual property of PS Pharm. did I appreciate that the above-identified application had been abandoned because I had not responded to the Notice.
8. The entire delay in responding the Notice was inadvertent and unintentional.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date:

July 2, 2002

Signed:




Steven R. King, Ph.D.

EL 477 037 113 US

1 GOLDBERG, STINNETT, MEYERS & DAVIS
2 A Professional Corporation
3 MERLE C. MEYERS, ESQ., CA Bar #66849
4 KATHERINE D. RAY, ESQ., CA Bar #121002
44 Montgomery Street, Suite 2900
San Francisco, California 94104
Telephone: (415) 362-5045

5 Attorneys for the Official
6 Committee of Unsecured Creditors



FILED
DEC 12 2001
UNITED STATES BANKRUPTCY COURT
SAN FRANCISCO, CA

7 IN THE UNITED STATES BANKRUPTCY COURT
8 FOR THE NORTHERN DISTRICT OF CALIFORNIA
9 SAN FRANCISCO DIVISION

10
11 In re

12 SHAMAN PHARMACEUTICALS, INC.,

13 Debtor.

Case No. 01-30035 TC

Under Chapter 11

RECEIVED

JUL 11 2002

OFFICE OF PETITIONS

14
15 ORDER APPROVING SALE AND ASSIGNMENT OF ASSETS

16 On or about October 19, 2001, SHAMAN PHARMACEUTICALS, INC., the debtor-in-
17 possession herein (the "Debtor"), filed its Notice of Motion and Motion to Sell Assets Free and Clear
18 of Liens, Claims and Interests, And to Assume and Assign Debtor's Contracts With Dr. Michael
19 Tempesta and General Nutrition Center (the "Sale Motion"), and on or about November 2, 2001,
20 Michael Tempesta, M.D. ("Dr. Tempesta") filed his Conditional Opposition of Dr. Michael Tempesta
21 To Debtor's Motion To Sell Assets, etc., (the "Tempesta Opposition"), conditionally objecting to the
22 relief sought in the Sale Motion. No other opposition or response with respect to the Sale Motion
23 was filed with the Court by any party.

24 On November 14, 2001, this Court filed the Order Approving Sale Procedures And
25 Compromise of Lien Disputes (the "Sale Procedures Order"). Pursuant to the terms of the Sale
26 Procedures Order and in full accordance with its requirements, an auction was conducted by the
27 Official Committee of Unsecured Creditors appointed herein (the "Committee") on November 15,
28 2001, and an offer by ~~accepted by the Bidder Lenders~~, as defined below, for the purchase of assets of

1 the estate herein was accepted, upon the terms set forth below. Thereafter, the Bridge Lenders
2 advised that they had designated as the recipient of the assets purchased PS Pharmaceuticals, Inc., a
3 corporation incorporated on or about November 15, 2001 in the State of Delaware ("New PS").

4 On November 16, 2001, following due and adequate notice, said matters, including the Sale
5 Motion, the Tempesta Opposition and confirmation of the sale and auction process conducted in
6 accordance with the provisions of the Sale Procedures Order, came before this Court for hearing.
7 Stephen D. Finestone, Esq. of Law Offices of Stephen D. Finestone appearing on behalf of the
8 Debtor, Merle C. Meyers, Esq. of Goldberg, Sinnamon, Meyers & Davis, A Professional Corporation
9 appearing on behalf of the Official Committee of Unsecured Creditors appointed herein (the
10 "Committee"), Michael St. James, Esq. of St. James Law appearing on behalf of WBW Trust
11 Number One, IBH-II LP, Robert M. Arnold, John W. Titcomb, Jr., H.W. Proctor and George
12 Rathmann (collectively, the "Bridge Lenders"), Todd E. Thompson, Esq. appearing on behalf of Dr.
13 Tempesta, and other counsel appearing as set forth in the record of this Court; and for good cause
14 shown,

15 NOW, THEREFORE, IT IS HEREBY ADJUDGED, DECREED AND ORDERED as
16 follows:

17 1. The Sale Motion is hereby GRANTED as and to the extent set forth hereinbelow, and
18 the Tempesta Opposition is hereby deemed WITHDRAWN.

19 2. Pursuant to the provisions of Sections 363(b), 363(f) and 365(b) of the Bankruptcy
20 Code, a sale of assets of the estate herein to New PS, including without limitation the assumption and
21 assignment of the Tempesta Licenses, as defined below, upon the following terms (collectively, the
22 "Subject Sale") is hereby authorized and approved:

23 A. Assets: The Debtor will transfer to New PS, free and clear of all liens and
24 other interests, but subject to the provisions of Sections 2.B. (cure of defaults) and 2.F.
25 (executing restated agreement with Dr. Tempesta), ownership of the following assets, to the
26 extent presently owned by the Debtor (the "Assets"): (i) the assets identified in collective
27 Schedule A hereto; (ii) assignment of all licenses and other agreements between the Debtor
28

1 and Dr. Tempesta (collectively, the "Tempesta Licenses") and (iii) the name, good will and
2 intangible assets associated with the name "P.S. Pharmaceuticals" and "Shaman
3 Pharmaceuticals". The Assets shall not include the following:

4 i. The latex and other property stored at United Cold Storage in South
5 San Francisco and 3 drums of latex and some blue and black 30 gallon containers of
6 research phase extracted latex on wooden pallets located at 217 East Grand Avenue,
7 South San Francisco.

8 ii. Any and all causes of action or claims that the estate may hold against
9 any party, including claims arising under Part V of the Bankruptcy Code; and

10 iii. Any executory contracts between the Debtor and General Nutrition
11 Corporation ("GNC"), as to which New PS will not take assignment, and the Debtor
12 will not assume.

13 B. Price: The Bridge Lenders will pay to the estate the amount of \$250,000.00,
14 and will assume any and all cure obligations under the Tempesta Licenses, up to the
15 maximum amount of \$25,000.00. The purchase price will be paid at closing, by application
16 of a \$150,000.00 deposit received and an additional cash payment of \$100,000.00.

17 C. Claim Waivers: As additional consideration to be provided by the Bridge
18 Lenders, the Bridge Lenders shall obtain and file a full release of all claims asserted by
19 Vulcan Ventures, Inc., in the approximate amount of \$500,000, against the Debtor or its
20 estate. In addition, pursuant to the terms of the Sale Procedures Order, the Bridge Lenders
21 and the Junior Lenders (as defined in the Sale Procedures Order) will release all claims and
22 liens against the Debtor or its estate with respect to any loans made by any of them to the
23 Debtor prior to or during the chapter 11 case.

24 D. As-is, Where-is: The assets will be transferred to New PS without
25 representation or warranty and on an "as-is, where-is" basis.

26 E. Closing: Closing of the sale shall occur as soon as practicable after entry of
27 this Order.
28

ET AL. (415)217-5910 415 434 1880 NO. 8561 P. 4 PAGE 6

F. Tempesta Documents: New PS agree (a) to execute a new license agreement with Dr. Tempesta in order to replace and integrate existing documents, provided that such new agreement does not contain any substantive changes from existing terms; and (b) that the description of calculation of royalty payments concerning GNC revenues, as executed by the Bridge Lenders' representative on November 15, 2001, is accurate and binding upon New PS.

3. As acknowledged and agreed by his counsel during the course of the aforementioned hearing before this Court, Dr. Tempesta (a) has agreed that the maximum amount of cure, if any, owing under the Tempesta License is \$25,000.00; and (b) has consented to the assumption and assignment of the Tempesta Licenses to New PS upon the terms and conditions set forth above.

4. The Debtor is hereby authorized and directed to take any and all action and to execute any and all documents necessary to effectuate the Subject Sale as described above.

DATED: December 12, 2001

Approved as to form and content:

ST. JAMES LAY

By:

Michael St. James, Esq.
Attorneys for the Bridge Lenders

HOWARD, RICE, NEMEROVSKI, CANADY BAIK & BAIK

By:

William J. Lafferty, Esq.
Attorneys for Michael T.

LAW OFFICES OF STEPHEN D. FINESTONE

L

Stephen D. Finestone, Esq.
Attorneys for the Debtor



UNITED STATES BANKRUPTCY COURT
Northern District of California
I certify that this is a true, correct and full copy
of the original document on file in my custody.
Dated 12-12-01
by James Chow
Deputy Clerk

12/12/2001 13:08 FAX 415 398 2820

VOGL & MEREDITH

002

1 ~~Tempesta License~~ New PS agree (a) to execute a new license agreement
2 with Dr. Tempesta in order to replace and integrate existing documents, provided that such
3 new agreement does not contain any substantive changes from existing terms; and (b) that the
4 description of calculation of royalty payments concerning GNC revenues, as executed by the
5 Bridge Lenders' representative on November 15, 2001, is accurate and binding upon New PS.

6 3. As acknowledged and agreed by his counsel during the course of the aforementioned
7 hearing before this Court, Dr. Tempesta (a) has agreed that the maximum amount of cure, if any,
8 owing under the Tempesta Licenses is \$25,000.00; and (b) has consented to the assumption and
9 assignment of the Tempesta Licenses to New PS upon the terms and conditions set forth above.

10 4. The Debtor is hereby authorized and directed to take any and all actions, and to
11 execute any and all documents, reasonably necessary to effectuate and consummate the Subject Sale
12 as described above.

13 DATED: November ____, 2001

14 THE HONORABLE THOMAS E. CARLSON
15 United States Bankruptcy Judge

16 Approved as to form and content:

17 ST. JAMES LAW

18 By:

19 Michael St. James, Esq.
20 Attorneys for the Bridge Lenders

21 HOWARD, RICE, NEMEROVSKI, CANADY, FALK & RABKIN

22 By:

23 William J. Lafferty, Esq.
24 Attorneys for Michael Tempesta, M.D.

25 LAW OFFICES OF STEPHEN D. FINESTONE

26 By:

27 Stephen D. Finestone, Esq.
28 Attorneys for the Debtor

**SCHEDULE A
ASSETS PURCHASED**

1. All assets associated with the SP-303 technology, see Schedule A-1
2. All intellectual property listed in the attached Schedule A-2, including but not limited to any and all IP related to SP-303
3. All of Shaman Pharmaceuticals rights, including Dietary Supplement rights, associated with the Bankruptcy Court approved sale of "Assets Purchase Agreement" between Shaman Pharmaceuticals and Metabolex Inc. dated March 16, 2001 and the "Second Amendment to License and Sale Agreement" also dated March 16, 2001.
4. All crude plant latex stored at H. Reisman Corporation in New Jersey.
5. All NSF and NSF-IB pills stored at FTI corporation and 213 and 317 East Grand Avenue.
6. All of Shaman's remaining laboratory equipment at 213, 317 East Grand Avenue.
7. All of Shaman furniture, Books, Journals, Artwork, Videos at 213 & 317 East Grand Ave.
8. Shaman's 4D research database, plant collections, extracts and Voucher specimens at 213 & 317 East Grand Avenue.
9. All of Shaman's remaining computer equipment and data contained within.
10. All paper records and data associated with SP-303 asset and plant research at Shaman, including laboratory notebooks at DATASAFE and paper files associated with Shaman's operations.
11. The following domain names and websites Shaman.com, Shamanbotanicals.com, NSFIB.com, diarrheasolutions.com and SyndromeXweb.com.
12. All remaining inventory of Syndrome X bars and SB-300 extract, all trademarks associated with Syndrome X and/or SP-303, SB-300, NSF-IB, NSF. The formulas for the Syndrome X bars and rights to use those formulas in syndrome x products.
13. The name of PS Pharmaceuticals Inc.
14. The Shaman Pharmaceuticals leaf logo.
15. All remaining rights of Shaman or PS Pharmaceuticals relating to the assignment of Shaman's lease to Tularik that was effective on April 10, 2001.
16. Forklift in 217 East Grand Avenue.

SCHEDULE A-1

Attachment I
to
Financing Statement
Shaman Pharmaceuticals, Inc.

The Financing Statement covers the following types or items of property:

(a) All intellectual property rights of any kind of Shaman Pharmaceuticals, Inc. related to SP303 and the SP303-Related Assets (as defined below), including without limitation P.S. Pharmaceutical's rights under the Tempesta License, and the U.S. Patents, U.S. Patent applications, and patent office prosecutions in Europe, North America and Asia which cover SP303 and NSF, and P.S. Pharmaceuticals know-how related to SP303. "SP303-Related Assets" means documents, records, inventory and personal property of the P.S. Pharmaceuticals related to SP303 and NSF, a dietary supplement with SP303 as the principal ingredient, including without limitation (a) documentation related to SP303 (including regulatory files, batch records, manufacturing procedures, technology, ethno-botanical information, databases and supplier information); (b) latex, a raw plant material used in making SP303 and NSF; (c) SB-300, essentially an uncompleted form of NSF; (d) NSF back inventory, which are tablets marketed and sold directly by P.S. Pharmaceuticals and through General Nutrition Centers; (e) completed SP303 compounds, which can be utilized for research purposes; and (f) U.S. patent # 5,211,944, U.S. patent # 5,494,661, US patent application serial # 09/066,989, US patent application serial # 09/243,197, US patent application serial # 09/364,248, Shaman docket # SHOBOT-08, and numerous related international and national patent office actions/prosecutions ongoing in Europe, North America and Asia (collectively, the "SP-303 Intellectual Property").

(b) Any and all goods, supplies, wares, merchandise, and other tangible personal property, including customer lists, latex/raw material, work in process, supplies and components, and finished goods that embody the SP-303 Intellectual Property, whether held for sale or lease or to be furnished under any contract for service or so leased or furnished, and also including products of and accessions to inventory, packing and shipping materials, and all documents of title, whether negotiable or nonnegotiable, representing any of the foregoing (collectively, the "Inventory").

(c) All rights of Shaman Pharmaceuticals, Inc. under its agreements for distribution of the Inventory, including without limitation, Shaman Pharmaceuticals' rights under an Agreement with GNC.

(f) All replacements, modifications and accessions to any of the foregoing, wherever located;

(g) All proceeds (including all insurance proceeds) of the foregoing; and

(h) All books, correspondence, records and other documents relating to the above-described property.

As used in this Security Agreement, the term "proceeds" includes whatever is receivable or received when collateral or the proceeds thereof is paid, collected or otherwise disposed of whether such disposition is voluntary or involuntary, and all claims arising out of the damage, destruction, or decrease in value of the collateral.

SCHEDULE A-2



System IP =

November 16, 2001

Docket No.	SP- No.	Drug Application	Patent Title	
7032-003	SP-1500	diabetes	Glucocorticoids and its use as a hypoglycemic agent.	5,019,580
7032-006	SP-1100	antifungal	Thiazobenzene antifungal and antifolate agents*	5,202,348
7032-007	SP-303	antiviral	Proanthocyanidin polymers having antiviral activity and methods of obtaining the same.	5,211,944
CIP				
7032-012	SP-1100	antifungal	Novel 1,2-dithiin antifolate agents (compound)	5,556,875
7032-013	SP-1100	antifungal	Class of phosphocholine derivatives having antifungal activity	5,681,829
7032-016	SP-303	antiviral	Methods for using Proanthocyanidin polymers having antiviral activity	5,494,661
7032-017	SP-1100	antifungal	Process For The Preparation Of Mono- And Bis(Phosphocholine) Derivatives Which Have Antifungal Activity	5,811,568
7032-019	SP-19502	antifungal	Novel and versatile methodology for the preparation of symmetrical and unsymmetrical 3,5-disubstituted-1,2-dithiins having antifungal activity	5,583,235
7032-020	SP-49701	diabetes	Hypoglycemic agent from cryptolepis	5,917,052
7032-021	SP-1100	antifungal	1,2-dithiins having antifungal activity	5,648,354
7032-022	SP-1100	antifungal	1,2-dithiins having antifungal activity	5,580,897
7032-023	SP-6700	diabetes	Fluorocyclopentylidene and oxaphosphorane derivatives for treatment of diabetes	5,747,527
7032-050	SP-49701	diabetes	Crystalline salts with hypoglycemic activity	5,681,958
7032-031	SP-49701	diabetes	Fluorocyclopentylidene salts from cyclopentanes (C5H10S)	5,628,999
7032-032	SP-49701	diabetes	Hypoglycemic agent from cyclopentanes (C5H10S)	5,629,319
7032-034	SP-49701	diabetes	Hypoglycemic agent from cyclopentanes (C5H10S)	5,753,790
7032-035	SP-1100	antifungal	Novel 1,2-dithiin antifolate agents (compounds)	5,668,168
7032-036	SP-18900	diabetes	Tartronic-type quinones for treatment of diabetes	5,674,900
7032-042	SP-8200	diabetes	Tricyclic compound for treatment of diabetes	5,691,386
7032-044	SP-134101	diabetes	Use of bisphenolic compounds to treat type II diabetes	5,827,898
7032-045	Nik Z	antifungal	Methods and compositions for treating fungal infections in mammals	5,789,387
7032-048	SP-4003	diabetes	Method of reducing blood glucose by administering Harungamin or Visamin	5,837,255

Purchased Assets
Schedule A-2
Page 2

7032-051	amitres:	diabetes	Analogs derivatives having antihyperglycemic activity	5,741,926
7032-059	SP-49701	diabetes	Methods of use of cryptolepine analogs with hypoglycemic activity	5,925,647

*assigned to University of British Columbia

8 Pending US applications (P&E)

Doc#	SP. No.	Drug/ Application classification	Patent Title	US Patent appl serial no.	Status
7032-069	SP-300		Basic formulations of procainylacyridin polymer and chemical compositions	09/066,989	Final Office Action, 3 month 08-15- 00; 6 month november 15, 2000 with fees
7032-062	phenyl piperazines	diabetes	Piperazine derivatives useful as hypoglycemic agents	08/993,320	brief re petition for retroactive license
7032-063	Indolizine epinephrine	diabetes	Indolizine/epinephrine derivatives with hypoglycemic activity	09/314,496 filed 05/19/99	Responded to restriction requirement
7032-069	Quindalones	diabetes	Quindoline compounds useful as hypoglycemic agents	09/340,468 filed 06/28/99	expect NTPMP
7032-070	48401/02	diabetes	Dihydrochalcones useful for the treatment of diabetes	filed 09/13/99	expect NTPMP
7032-071	SP-4009	diabetes	Anthracene compounds as hypoglycemic agents	filed 09/13/99	expect NTPMP
7032-072	GB-300	MS	Basic formulations of procainylacyridin polymer and chemical compositions and methods of preparation	Filed 02/01/00	

PENDING US APPLICATIONS (SHAMLAN IN HOUSE)

DocId No.	SP No.	Drug Application	Patent Title	US Patent appl serial no.	Status
SHBOT-01	SB-300-01	diarrhea	Enteric formulations of proanthocyanidin polymer antidiarrheal compositions	09/243,197 f/d 02/01/99	awaiting Office Action
SHBOT-02	SB-300-01	diarrhea	Stabilized bicyclo [3.3.1]nonenes and methods of use	09/270,305 f/d 09/15/99	awaiting Office Action
SHBOT-03	SB-300-01	diarrhea	Methods of using isolated and purified bicyclo[3.3.1]nonenes for treating diabetes and hypertriglyceridemia	09/270,489 f/d 03/15/99	awaiting Office Action
SHBOT-04	SB-300-01	diarrhea	Methods of using isolated and purified bicyclo[3.3.1]nonenes for treating depression	provisional f/d 03/15/99	Convert to actual application by 03/15/00
SHBOT-05	SB-300-01				
SHBOT-06	SB-300-01	diarrhea	Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same	09/364,248 filed 07/29/99	NTFMP due 10-24-99 to 02-24-99
SHBOT-08	SB-300	diarrhea	Use Of Branched Proanthocyanidin Polymer Extract By Mammals Suffering From Secretory Diarrhea		
SHBOT-14	SP-49400	diabetes	Use of Branched Polymers Extracts to treat hyperglycemia & control blood glucose levels	In process	
SHBOT-15	SP-49400	diabetes	Use of Branched Polymers Extracts to treat hyperglycemia & control blood glucose levels	In process	

FOREIGN APPLICATIONS/PATENTS (Y & E)

Doc. No.	SP. No.	Country	Patent Title	Patent/appl. serial no.	Status
7032-007-01	SP-303	Canada (01) Australia (007) New Zealand (04) Mexico (09) Japan (12) Singapore (23) Rep. of Korea (187) EPC (237)	Enantiomeric formulations of proanthocyanidin polymer antidiarrhoeal compositions	various	various stages still pending, issued Aus (form for acceptance 06-05-01), NZ, Mex
7032-012	SP-1160	Japan (17)	Novel 1,2-dibenzyl esters (compound)	09/270,305 E/4 03/13/99	Examination requested
7032-013		Japan	Novel 1,2-dibenzyl esters (compound) having antibacterial activity	06-51(1144)	Request for Examination Due October 8, 2000
7032-014	SP-4700	Taiwan	Novel compositions and methods for the treatment of diabetes	NI093964	Issued
7032-016	SP-1890	Taiwan	Novel compositions and methods for the treatment of diabetes	83-106793	Awaiting examination
7032-019	SP-303	Mexico	Novel compositions and methods for the treatment of diabetes	9603703	Pending
7032-046	SP-303	Australia (02)	Enantiomeric formulations of proanthocyanidin polymer antidiarrhoeal compositions	49881/97	Pending must be put into condition for allowance by April 5, 2002 (outstanding office action)
7032-062	Phanyl P1perai	International PCT			

7052-472	nes	designating everyone			
	339-909	118a	Entire formulations of proanthocyanidin polymer sequestered dietary supplements and methods of preparing same	Filed 02/01/00 PCT/US00/02 687	National Stage filings due 08-01-01

EPC filing includes: Austria, Belgium, France, Germany, Italy, Luxembourg, Netherlands, Sweden, United Kingdom, Greece, Spain and Denmark

7032-046	SP-303	Canada, Australia, Mexico, Japan, Korea, Philippines, Taiwan, Rep. of Korea, KPC,	Essenic Formulations of Proanthocyanidin Polymers	Pending	various stages
7032-048	SP-4003	Taiwan	Method of reducing blood glucose by administering Hesperidin or Vignin	Pending	
7032-049	Phen-Fip	PCT	Phenol derivatives useful as hypoglycemic agents	pending note: 30 month date 06/18/00	Abandoned
7032-072	SB-300	PCT	Essenic formulations of Proanthocyanidin polymer enriched dietary supplements and methods of preparing same	pending	Demand filed Nationals Stage August 1, 2001

SUMMARIES

SP-303 issued United States Patents 5,211,944 (Polymers) and 5,494,661 (Methods of Use); Issued patents in Australia, New Zealand, Mexico; Examination pending in Japan, Korea and Singapore; National Stage validation filed in United Kingdom and Netherlands (October 5, 2000).

SB-300 2 pending US applications, PCT application designating everyone filed earlier this year; National Stage applications due to be filed August 1, 2001.